Estimation of Infection Force of Hepatitis C Virus Among Drug Users in France

被引:6
|
作者
Kasereka, Selain [1 ]
Le Strat, Yann [2 ]
Leon, Lucie [2 ]
机构
[1] Univ Kinshasa, Kinshasa, DEM REP CONGO
[2] French Natl Publ Hlth Agcy, Sante Publ France, St Maurice, Ile De France, France
来源
RECENT ADVANCES IN NONLINEAR DYNAMICS AND SYNCHRONIZATION: WITH SELECTED APPLICATIONS IN ELECTRICAL ENGINEERING, NEUROCOMPUTING, AND TRANSPORTATION | 2018年 / 109卷
关键词
INJECT DRUGS; PEOPLE; PREVENTION; AUSTRALIA; MORTALITY;
D O I
10.1007/978-3-319-58996-1_15
中图分类号
TM [电工技术]; TN [电子技术、通信技术];
学科分类号
0808 ; 0809 ;
摘要
The spread of diseases is a dynamic and complex phenomenon. In the world, they are due to misery and poverty. To understand epidemiological systems is essential for governments. Since modeling simplifies reality, it is an excellent method. The hepatitis C virus (HCV) infection is common worldwide, and injection drug use remains the major mode of transmission of the disease, especially because of equipment sharing. Consequently, it is crucial to monitor the HCV transmission dynamics over time and to assess the effect of harm reduction measures. The aim of this work is to estimate the force of infection of hepatitis C from two national cross-sectional epidemiological surveys conducted in 2004 and 2011 by the French Institute for Public Health Surveillance and its partners in a drug user population in France. HCV prevalence was estimated according to age and calendar time through fractional polynomials adjusted or not to the HIV serological status and to injected drug users or oral drug users in general. The force of infection was modeled according to an SIS (susceptible-infected-susceptible) compartmental model using ordinary differential equations (ODE) and as a function of the derivative of the prevalence function depending on age, time, HIV serological status, and having injected at least once in their life, from 2000 to 2020. Our model was applied on real and simulated surveys using R and Stata software. The results show that HCV prevalence and the force of infection are linked to age and time, and are very high for drug users who injected at least once in their life and who are simultaneously HCV and HIV infected. Based on this model, we estimated that HCV incidence will continue to decline over the following years. Currently in France, there is no cohort study of the HCV among drug users. The only way to estimate HCV incidence in the French population is to use the only existing two national cross-sectional surveys. Our work provides guidance for researchers to compare several cross-sectional epidemiological surveys among drug users and proposes an alternative method to estimate the force of infection among drug users from cross-sectional surveys in the absence of a cohort.
引用
收藏
页码:319 / 344
页数:26
相关论文
共 50 条
  • [1] Recommendations for the management of hepatitis C virus infection among intravenous drug users
    Grebely, Jason
    Robaeys, Geert
    Bruggmann, Philip
    Aghemo, Alessio
    Backmund, Markus
    Bruneau, Julie
    Byrne, Jude
    Dalgard, Olav
    Feld, Jordan J.
    Hellard, Margaret
    Hickman, Matthew
    Kautz, Achim
    Litwin, Alain
    Lloyd, Andrew R.
    Mauss, Stefan
    Prins, Maria
    Swan, Tracy
    Schaefer, Martin
    Taylor, Lynn E.
    Dore, Gregory J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2023, 111
  • [2] Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy
    Spada, Enea
    Rezza, Giovanni
    Garbuglia, Anna Rosa
    Lombardo, Flavia Lucia
    Zuccaro, Ornella
    Ippolito, Francesca Menniti
    Cupellaro, Elisabetta
    Capone, Stefania
    Capobianchi, Maria Rosaria
    Nicosia, Alfredo
    Cortese, Riccardo
    Folgori, Antonella
    Mele, Alfonso
    JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2018, 95 (01): : 99 - 110
  • [3] Prevention of hepatitis C virus infection in drug users
    Schulte, B.
    Stoever, H.
    Leicht, A.
    Schnackenberg, K.
    Reimer, J.
    BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ, 2008, 51 (10) : 1210 - 1217
  • [4] Hepatitis C virus infection in Irish drug users and prisoners - a scoping review
    Crowley, D.
    Murtagh, R.
    Cullen, W.
    Lambert, J. S.
    McHugh, T.
    Van Hout, M. C.
    BMC INFECTIOUS DISEASES, 2019, 19 (01)
  • [5] The importance of preventing hepatitis C virus infection among injection drug users in the United States
    Alter, MJ
    Moyer, LA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 18 : S6 - S10
  • [6] Hepatitis C Virus Infection and Related Risk Factors among Injection Drug Users in Montenegro
    Bacak, Valerio
    Lausevic, Dragan
    Mugosa, Boban
    Vratnica, Zoran
    Terzic, Natasa
    EUROPEAN ADDICTION RESEARCH, 2013, 19 (02) : 68 - 73
  • [7] Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
    de Vos, Anneke S.
    van der Helm, Jannie J.
    Matser, Amy
    Prins, Maria
    Kretzschmar, Mirjam E. E.
    ADDICTION, 2013, 108 (06) : 1070 - 1081
  • [8] Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: Implications for prevention
    Hutchinson, SJ
    Bird, SM
    Taylor, A
    Goldberg, DJ
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2006, 17 (03) : 211 - 221
  • [9] Risk of hepatitis C virus infection among heroin and methamphetamine users
    Okruhlica, Lubomir
    Kamendy, Zuzana
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2019, 21 (04) : 23 - 26
  • [10] Prävention der Hepatitis C bei DrogenkonsumentenPrevention of hepatitis C virus infection in drug users
    Bernd Schulte
    H. Stöver
    A. Leicht
    K. Schnackenberg
    J. Reimer
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2008, 51 : 1210 - 1217